Skip to content
Screener

Integra LifeSciences IART Private Label — Total Revenues

Other product segments

Neurosurgery
$213.26M+2.0%
Wound Reconstruction
$79.65M+6.5%
Instruments
$47.23M-7.3%
ENT
$37.71M-2.8%

Similar metrics at other companies

ESP
ESPRCollaboration revenue — Total Revenues
$36.71M+22.0%
CME Group logo
CMEOther Revenue — Total Revenues
$115.6M+9.2%
AMR
AMRZInterproduct revenues — Total Revenues
-$151M-3.4%
NorthWestern Energy Group, Inc. logo
NWETotal Revenue — Total Revenues
$497.57M+6.6%
Host Hotels & Resorts logo
HSTRooms — Total Revenues
$954M+0.5%
Host Hotels & Resorts logo
HSTOther — Total Revenues
$149M-6.3%

Other financials

Income statement

See full
Revenue$418.8M+0.8%
Gross profit$219.7M+5.0%
Operating income$19.3M+104%
Net income$4.5M+101%
EPS (diluted)$0.06+101%

Balance sheet

See full
Cash & equivalents$214.4M-1.6%
Total debt$2.0B+3.2%
Total equity$1.0B+0.5%
Total assets$3.6B-2.8%

Cash flow

See full
Operating cash flow$22.8M+156%
CapEx$12.3M-38.9%
Free cash flow$10.5M+193%

Valuation

See full
Market cap$1.33B+38.0%
Enterprise value$3.08B+16.2%
P/S0.8×+0.2×

Profitability

See full
Gross margin52.5%-0.1pp
Operating margin2.6%+1.3pp
Net margin-0.4%—
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-0.7%—
Debt / equity1.9×+0.1×
Current ratio3.6×+2.4×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Integra LifeSciences’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:03 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000917520-26-000058
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Neurosurgery$213,264$208,992$411,458$399,904
Surgical Instruments54,80653,080102,039104,030
ENT Solutions41,19941,88678,90780,688
Total Specialty Surgery309,269303,958592,404584,622
Wound Reconstruction Solutions81,30584,747160,952159,526
Private Label28,18726,90057,32354,110
Total Tissue Reconstruction109,492111,647218,275213,636
Total Revenue$418,761$415,605$810,679$798,258

Item 1. Financial Statements

FAQ

What is Integra LifeSciences's private label — total revenues?
Integra LifeSciences (IART) reported private label — total revenues of $28.19M in Q2 2026.
How has Integra LifeSciences's private label — total revenues changed year-over-year?
Integra LifeSciences's private label — total revenues increased by 4.8% year-over-year, from $26.9M to $28.19M.
What is the long-term trend for Integra LifeSciences's private label — total revenues?
Over 4 years (2021 to 2025), Integra LifeSciences's private label — total revenues has grown at a -2.8% compound annual growth rate (CAGR), from $124.75M to $111.25M.
What does private label — total revenues mean?
This metric represents the total net revenue generated from products manufactured by the company and sold under third-party brand names. It reflects the commercial performance and market demand for the company's contract manufacturing and private label business segment.

Ask your AI about Integra LifeSciences's private label — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude